Pfizer
Pfizer Reduces Stake in BioNTech; Candel Pauses Pancreatic Cancer Program
Pfizer; BioNTech; stake reduction; Candel Therapeutics; pancreatic cancer; Comirnaty; mRNA vaccine; Metsera acquisition; pipeline expansion
Pfizer Closes Metsera Deal, Officially Ending Bidding War Drama
Pfizer; Metsera; acquisition; Novo Nordisk; bidding war; obesity drugs; GLP-1; CVR; regulatory certainty
Pfizer Triumphs Over Novo Nordisk with $10B Bid to Acquire Metsera
Pfizer; Novo Nordisk; Metsera; obesity drugs; GLP-1; acquisition; bidding war; shareholder approval; pharmaceutical industry
Novo Nordisk Ups the Stakes With $10B Bid for Metsera, Surpassing Pfizer’s Offer
Novo Nordisk; Pfizer; Metsera; bidding war; acquisition; $10 billion; contingent value right; pharmaceutical industry; antitrust litigation
Delaware Court Denies Pfizer’s Bid to Block Novo Nordisk-Metsera Deal
Delaware Court; Pfizer; Novo Nordisk; Metsera; temporary restraining order; merger agreement; antitrust; FTC; obesity drugs
Metsera Bidding War Grips Obesity Drug Field as Novo Nordisk and Pfizer Escalate Offers
Metsera; obesity drugs; bidding war; Novo Nordisk; Pfizer; acquisition; GLP-1; antitrust; market dominance; legal disputes
Novo Execs Face Skeptical Analysts Amid Metsera Buyout Drama
Novo Nordisk; Metsera; acquisition; Pfizer; buyout; obesity drugs; analysts; lawsuit; antitrust; CEO Mike Doustdar
Pfizer Cuts 11 R&D Programs amid Ongoing Revenue Declines and Cost Realignment Efforts
Pfizer; R&D cuts; revenue decline; cost savings; Q3 2025 earnings; COVID-19 product sales; digital enablement; AI in R&D; Seagen acquisition
Novo Nordisk Ups Metsera Bid to $10 Billion to Top Pfizer’s Offer
Novo Nordisk; Metsera; Pfizer; M&A; biotech acquisition; contingent value right; obesity drugs; diabetes treatments
Metsera Calls Pfizer’s Threats ‘Nonsense’ as Rift Between Companies Widens
Metsera; Pfizer; Novo Nordisk; merger dispute; litigation; obesity drug acquisition; regulatory approval; Delaware Court of Chancery